India Life Science Tools Market By Technology (Genomic, Proteomics, Cell Biology, Others), By Product (Cell Culture Systems & 3D Cell Culture, Liquid Chromatography, Mass Spectrometry, Flow Cytometry, Cloning & Genomic Engineering, NGS, Microscopy, PCR, Others), By End Use (Government, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Life Science Tools Market was valued at USD 913.72 Million in 2024 and is expected to reach USD 1,341.94 Million by 2030 with a CAGR of 6.46% during the forecast period. The India Life Science Tools Market is experiencing rapid growth, driven by the expansion of the biopharmaceutical and biotechnology sectors, increasing investments in research and development (R&D), and the rising adoption of genomics, proteomics, and molecular diagnostics. The presence of a strong pharmaceutical base in Maharashtra and Gujarat, coupled with biotech hubs in Bengaluru and Hyderabad, has positioned India as a key market for life science tools. Government initiatives such as the Genome India Project, Production Linked Incentive (PLI) scheme, and funding from ICMR and DBT are accelerating advancements in genomics, precision medicine, and drug discovery, further boosting demand for high-end analytical instruments and reagents. Additionally, the increasing burden of chronic diseases like cancer and diabetes is driving demand for molecular diagnostics, gene sequencing, and cell biology tools.

However, the market faces challenges such as high costs of advanced technologies, limited skilled workforce, and dependency on imported equipment, which increases operational expenses for research institutions and pharmaceutical firms. While government incentives encourage domestic manufacturing, India still lags in developing high-end genomic and proteomic analysis tools, making affordability a key concern. Infrastructure gaps in tier-2 and tier-3 cities also restrict market penetration, limiting accessibility to cutting-edge life science research. Despite these challenges, the entry of global players, increased foreign investments, and a growing focus on personalized medicine are expected to drive sustained growth in the Indian life science tools market in the coming years.

Key Market Drivers

Expansion of Biotechnology Sector

India's biotechnology sector has witnessed remarkable expansion over the past decade, emerging as a pivotal driver of economic growth and innovation. In 2014, the industry's valuation stood at approximately $10 billion; by 2024, it had surged to over $130 billion, with projections aiming for $300 billion by 2030.

This exponential growth is underpinned by a robust startup ecosystem, significant government initiatives, and a burgeoning bioeconomy. The startup landscape has been particularly dynamic. From a modest count of around 300 biotech startups in 2012, the number escalated to over 9,000 by 2024. These startups span diverse domains, including health-tech, diagnostics, agriculture, and bioinformatics, contributing to over 800 innovative products and attracting $600 million in follow-on funding. This surge not only fosters innovation but also positions India as a global hub for biotechnology solutions.

Government support has been instrumental in this trajectory. The flagship Startup India program, launched in 2016, has recognized over 157,000 startups across sectors as of December 2024, streamlining compliance and offering tax benefits to nurture entrepreneurial ventures. Specific to biotechnology, the Biotechnology Industry Research Assistance Council (BIRAC) has played a pivotal role since its inception in 2012, fostering innovation and facilitating the transition of research from laboratories to market-ready applications. This concerted effort has cultivated a conducive environment for biotech enterprises to thrive. The bioeconomy, encompassing all economic activity derived from biotechnological research and innovation, has expanded from $10 billion in 2014 to over $130 billion in 2024.

This growth is driven by increasing demand for biopharmaceuticals, vaccines, and sustainable agricultural solutions. Notably, India accounts for 60% of global vaccine production and houses the second-largest number of USFDA-approved manufacturing plants outside the United States, underscoring its critical role in global healthcare.

Growing Demand for Precision Medicine & Diagnostics

The growing demand for precision medicine and diagnostics is revolutionizing healthcare in India, driven by advancements in genomics, molecular biology, and artificial intelligence (AI)-based diagnostics. With an increasing focus on personalized treatment approaches, healthcare providers are shifting away from a one-size-fits-all model to targeted therapies tailored to an individual's genetic profile, lifestyle, and disease susceptibility. This transformation is being fueled by the increasing accessibility of next-generation sequencing (NGS), biomarker-based diagnostics, and companion diagnostics, enabling early disease detection and more effective treatment plans.

One of the key drivers of this demand is the rising prevalence of chronic diseases, including cancer, cardiovascular disorders, and diabetes, where traditional treatment approaches often yield suboptimal results. Genetic testing and molecular diagnostics allow for early-stage detection and risk assessment, improving patient outcomes and reducing healthcare costs in the long run. Additionally, the rapid integration of AI and big data analytics into diagnostics has enhanced accuracy, speed, and predictive capabilities, further strengthening the adoption of precision medicine.

The increasing role of pharmacogenomics in drug development and treatment customization is another significant factor boosting this trend. As more pharmaceutical companies collaborate with biotech firms to develop targeted therapies, the need for companion diagnostics—which help determine a patient’s likelihood of responding to a specific drug—has surged. This has led to a greater demand for advanced diagnostic tools, such as liquid biopsies, gene expression profiling, and proteomics-based tests, which enable real-time monitoring of disease progression and treatment efficacy.

Moreover, government initiatives and regulatory support are fostering the growth of precision medicine in India. Programs focused on genomic research, AI-driven healthcare solutions, and digital health records are paving the way for more personalized treatment strategies. The increasing affordability and accessibility of genetic testing services are also contributing to the expansion of precision diagnostics beyond urban centers, reaching a wider patient population.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Technologies

One of the biggest challenges in the Indian life science tools market is the high cost of advanced technologies, which limits accessibility and adoption, especially among smaller research institutions, diagnostic labs, and pharmaceutical startups. Many cutting-edge tools used in genomics, proteomics, and cell biology, such as next-generation sequencing (NGS), mass spectrometry, and high-throughput screening systems, require significant capital investment. These technologies often involve not just the upfront cost of acquisition, but also substantial expenses related to maintenance, consumables, and skilled personnel training, making them financially burdensome for many players in the market.

India’s dependency on imported equipment further escalates costs. A majority of high-end life science tools are sourced from international manufacturers, leading to increased expenses due to import duties, currency fluctuations, and logistical costs. Unlike developed countries, where governments and private sector investments significantly subsidize R&D, many Indian research institutions operate on constrained budgets, limiting their ability to invest in advanced analytical instruments. This creates a gap in technological accessibility between elite research centers in metro cities and smaller institutions in tier-2 and tier-3 cities, slowing down overall innovation and scientific progress.

Moreover, while government initiatives such as the Atmanirbhar Bharat (Self-Reliant India) initiative aim to promote local manufacturing of high-tech scientific instruments, the domestic production of life science tools is still in its nascent stage. India’s biotech and pharmaceutical sectors rely heavily on imported components and reagents, further increasing operational costs. Limited availability of affordable, high-precision domestic alternatives mean researchers and companies often have to compromise on the quality or scale of their studies due to budgetary constraints.

Key Market Trends

Growing Biopharmaceutical Industry

The rapid expansion of India’s biopharmaceutical industry is emerging as a major trend shaping the life science tools market. With increasing demand for biosimilars, vaccines, monoclonal antibodies, and gene therapies, the biopharma sector is driving significant investment in advanced research tools, analytical technologies, and high-throughput screening systems. The shift from traditional small-molecule drugs to biologics has necessitated the adoption of sophisticated life science instruments for protein analysis, cell culture, and bioprocessing, fueling market growth.

One of the major factors contributing to this trend is the rising global demand for cost-effective biologics and biosimilars, where India has positioned itself as a key player. Indian pharmaceutical companies are leveraging their expertise in generic drug manufacturing to enter the biosimilar market, leading to increased investments in R&D, regulatory compliance, and advanced analytical tools. With a strong presence of contract development and manufacturing organizations (CDMOs), the country is becoming a hub for outsourced biopharmaceutical research and production, further amplifying the need for cutting-edge life science tools.

The rising adoption of personalized medicine and the growing emphasis on cell and gene therapies are expanding the need for high-end analytical techniques such as mass spectrometry, flow cytometry, and chromatography. Companies are increasingly focusing on process optimization and automation to improve the efficiency and scalability of biopharmaceutical production, leading to higher adoption of single-use bioprocessing systems, biosensors, and AI-driven quality control mechanisms.

Segmental Insights

Product Insights

Based on Product, Next-Generation Sequencing (NGS) have emerged as the dominating segment in the India Life Science Tools Market in 2024, driven by its expanding applications in genomic research, precision medicine, cancer diagnostics, and infectious disease detection. The increasing adoption of whole-genome sequencing, transcriptomics, and epigenetics studies has fueled the demand for NGS technology in clinical diagnostics, drug development, and personalized healthcare.

The Genome India Project, aimed at sequencing the diverse genetic makeup of the Indian population, has significantly boosted the use of NGS tools. Additionally, the growing prevalence of genetic disorders, rare diseases, and cancer, along with the decreasing cost of sequencing, has accelerated market penetration. The use of NGS in non-invasive prenatal testing (NIPT), pharmacogenomics, and microbiome research has further strengthened its position as the leading product category.

End Use Insights

Based on End Use, Pharmaceutical & Biotechnology Companies have emerged as the dominating segment in the India Life Science Tools Market in 2024. The growing investment in R&D, clinical trials, and precision medicine has fueled the demand for advanced analytical instruments, genomic sequencing tools, and bioprocessing technologies within this sector.

India’s strong position as a global pharmaceutical manufacturing hub, particularly in biosimilars, vaccines, and monoclonal antibodies, has led to increased adoption of next-generation sequencing (NGS), mass spectrometry, flow cytometry, and chromatography systems. The rise of contract development and manufacturing organizations (CDMOs), catering to global biotech and pharma firms, has further strengthened the demand for life science tools.

Government support through initiatives like the Production-Linked Incentive (PLI) scheme and the National Biopharma Mission has encouraged pharmaceutical and biotech firms to invest in cutting-edge research infrastructure. With increasing focus on personalized medicine, regenerative therapies, and AI-driven drug discovery, pharmaceutical and biotechnology companies remain the leading end-user segment, driving growth in India's life science tools market.

Download Free Sample Report

Regional Insights

Based on Region, West India have emerged as the dominating region in the India Life Science Tools Market in 2024. It is driven by its strong presence of pharmaceutical and biotechnology hubs, leading research institutions, and a well-established healthcare ecosystem. States like Maharashtra and Gujarat have played a crucial role in propelling the market forward due to their concentration of pharma manufacturing, contract research organizations (CROs), and life science startups.

Maharashtra, particularly Mumbai and Pune, houses major pharmaceutical giants, research institutes, and biotech parks. It is a key center for clinical research, drug discovery, and genomics applications, boosting the demand for life science tools such as NGS, PCR, mass spectrometry, and chromatography systems. The presence of top academic and research institutions such as the National Institute for Research in Reproductive Health (NIRRH) and the Indian Institute of Science Education and Research (IISER) further supports market growth.

Recent Development

• In December 2024, ACG Inspection is set to launch its Life Sciences Cloud, an end-to-end analytical and traceability solution designed to enhance production quality, manufacturing efficiency, and supply chain transparency. This innovative platform empowers pharmaceutical companies with real-time insights, compliance support, and digital transformation, ensuring a more efficient, secure, and high-quality supply chain for a healthier world.
• In June 2024, Schneider Electric has launched EcoStruxure for Life Sciences, a digital automation and energy management solution aimed at accelerating sustainability in India’s pharmaceutical industry. The platform enhances efficiency, compliance, and carbon footprint reduction through IoT, AI, and data-driven insights, helping pharma companies achieve sustainable manufacturing, energy optimization, and regulatory adherence while ensuring operational resilience and cost savings.
• In February 2024, C-CAMP has launched a Life Science Entrepreneurship Development Programme to foster problem-solving and innovation within India’s academic community. This initiative aims to equip researchers and students with entrepreneurial skills, industry insights, and business acumen, enabling them to translate scientific discoveries into impactful life science ventures, driving innovation and economic growth in the sector.
• In June 2023, Revvity was officially launched as a science-driven solutions company, focusing on life sciences and diagnostics. The company aims to advance drug discovery, precision medicine, and clinical diagnostics with cutting-edge technologies in genomics, imaging, and analytical tools. Revvity's launch marks a strategic move to enhance global healthcare innovation and scientific research capabilities across diverse sectors.

Key Market Players

• Becton Dickinson India Private Limited
• Agilent Technologies India Private Limited
• Illumina Inc.
• Thermo Fisher Scientific Inc
• Roche Products India Private Limited
• Bio-Rad Laboratories India Private Limited
• Merck Life Science Private Limited
• Wipro GE Healthcare Private Limited
• Bruker India Scientific Pvt Ltd
• Qiagen India Private Limited

Report Scope

In this report, the India Life Science Tools Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Life Science Tools Market, By Technology:

o   Genomic

o   Proteomics

o   Cell Biology

o   Others

• India Life Science Tools Market, By Product:

o   Cell Culture Systems & 3D Cell Culture

o   Liquid Chromatography

o   Mass Spectrometry

o   Flow Cytometry

o   Cloning & Genomic Engineering

o   NGS

o   Microscopy

o   PCR

o   Others

• India Life Science Tools Market, By End Use:

o   Government

o   Pharmaceutical & Biotechnology Companies

o   Academic & Research Institutions

o   Others

• India Life Science Tools Market, By Region:

o   East India

o   West India

o   North India

o   South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Life Science Tools Market.

Available Customizations:

India Life Science Tools Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Life Science Tools Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com